Oxaliplatin News and Research

RSS
DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

Ups and downs of incorporating new treatment to reduce oxaliplatin-induced neuropathy

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

Hutchison MediPharma achieves primary endpoint in POC Phase II study to treat NSCLC patients

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Genes could help physicians make informed treatment decisions for metastatic colorectal cancer patients

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Uninsured cancer patients may face higher charges for chemotherapy drugs

Uninsured cancer patients may face higher charges for chemotherapy drugs

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

EMA extends approval of Vectibix plus FOLFIRI as first-line treatment for wild-type RAS mCRC

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

XenOPAT aims to advance development of new drugs against cancer, personalized cancer treatments

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer